Exploiting acquired vulnerability to develop novel treatments for cholangiocarcinoma
Abstract Cholangiocarcinoma (CCA) presents a formidable therapeutic challenge due to its extensive heterogeneity and plasticity, which inevitably lead to acquired resistance to current treatments. However, recent evidence suggests that acquired drug resistance is associated with a fitness cost resul...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2024-11-01
|
| Saila: | Cancer Cell International |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s12935-024-03548-2 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|